BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11232950)

  • 21. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
    Lokich JJ; Anderson N; Bern M; Coco F; Dow E
    Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
    Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
    Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
    Miller VA; Ng KK; Krug LM; Perez W; Pizzo B; Heelan RT; Kris MG
    Cancer; 2000 Mar; 88(5):1045-50. PubMed ID: 10699893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
    Crawford J; O'Rourke MA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
    Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
    J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of vinorelbine and paclitaxel in small-cell lung cancer.
    Iaffaioli RV; Facchini G; Tortoriello A; Caponigro F; Illiano A; Gentile M; Gravina A; Muto P
    Cancer Chemother Pharmacol; 1997; 41(1):86-90. PubMed ID: 9443619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
    Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
    Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer.
    Chang AY; Garrow GC
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):66-70; discussion 70-1. PubMed ID: 7740336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
    J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel combined with vinorelbine: phase I results and new study designs.
    Fumoleau P; Féty R; Delecroix V; Perrocheau G; Azli N
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):29-31. PubMed ID: 9213325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma.
    Cocconi G; Mambrini A; Quarta M; Vasini G; Bella MA; Ferrozzi F; Beretta MD
    Cancer; 2000 Jun; 88(12):2731-8. PubMed ID: 10870055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study.
    Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Grandinetti P; Cognetti F
    Cancer Chemother Pharmacol; 2000; 45(6):513-5. PubMed ID: 10854141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.